Lisa M Greene

Lisa M Greene,

Fiscal Assistant I

Department: MD-BIOCHEM / MOLECULAR BIOL
Business Phone: (352) 294-8409
Business Email: lisa.greene@ufl.edu

Publications

2018
Involvement of NF-κB in mediating the anti-tumour effects of combretastatins in T cells.
Investigational new drugs. 36(4):523-535 [DOI] 10.1007/s10637-017-0543-z. [PMID] 29460212.
2018
Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.
Journal of medicinal chemistry. 61(2):514-534 [DOI] 10.1021/acs.jmedchem.6b01917. [PMID] 28426931.
2017
β-Lactam analogues of combretastatin A-4 prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cells.
European journal of medicinal chemistry. 130:261-285 [DOI] 10.1016/j.ejmech.2017.02.049. [PMID] 28254699.
2016
Inhibition of γ-secretase activity synergistically enhances tumour necrosis factor-related apoptosis-inducing ligand induced apoptosis in T-cell acute lymphoblastic leukemia cells via upregulation of death receptor 5.
Oncology letters. 12(4):2900-2905 [PMID] 27698877.
2016
Pre-clinical evaluation of a novel class of anti-cancer agents, the Pyrrolo-1, 5-benzoxazepines.
Journal of Cancer. 7(15):2367-2377 [PMID] 27994676.
2016
Synthesis and Biochemical Evaluation of 3-Phenoxy-1,4-diarylazetidin-2-ones as Tubulin-Targeting Antitumor Agents.
Journal of medicinal chemistry. 59(1):90-113 [DOI] 10.1021/acs.jmedchem.5b01086. [PMID] 26680364.
2016
The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15.
Investigational new drugs. 34(2):159-67 [DOI] 10.1007/s10637-016-0331-1. [PMID] 26885657.
2016
The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL‑induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells.
International journal of oncology. 49(1):74-88 [DOI] 10.3892/ijo.2016.3518. [PMID] 27176505.
2015
Combretastatins: more than just vascular targeting agents?
The Journal of pharmacology and experimental therapeutics. 355(2):212-27 [DOI] 10.1124/jpet.115.226225. [PMID] 26354991.
2013
Combretazet-3 a novel synthetic cis-stable combretastatin A-4-azetidinone hybrid with enhanced stability and therapeutic efficacy in colon cancer.
Oncology reports. 29(6):2451-8 [DOI] 10.3892/or.2013.2379. [PMID] 23564200.
2013
Inhibition of late-stage autophagy synergistically enhances pyrrolo-1,5-benzoxazepine-6-induced apoptotic cell death in human colon cancer cells.
International journal of oncology. 43(3):927-35 [DOI] 10.3892/ijo.2013.1989. [PMID] 23799546.
2013
Novel cis-restricted β-lactam combretastatin A-4 analogues display anti-vascular and anti-metastatic properties in vitro.
Oncology reports. 29(2):585-94 [DOI] 10.3892/or.2012.2181. [PMID] 23232969.
2013
Synthesis and biochemical activities of antiproliferative amino acid and phosphate derivatives of microtubule-disrupting β-lactam combretastatins.
European journal of medicinal chemistry. 62:705-21 [DOI] 10.1016/j.ejmech.2013.01.016. [PMID] 23454513.
2012
The vascular targeting agent Combretastatin-A4 directly induces autophagy in adenocarcinoma-derived colon cancer cells.
Biochemical pharmacology. 84(5):612-24 [DOI] 10.1016/j.bcp.2012.06.005. [PMID] 22705646.
2011
BubR1 is required for the mitotic block induced by combretastatin-A4 and a novel cis-restricted ß-lactam analogue in human cancer cells.
International journal of molecular medicine. 27(5):715-23 [DOI] 10.3892/ijmm.2011.633. [PMID] 21369694.
2011
Synthesis, biochemical and molecular modelling studies of antiproliferative azetidinones causing microtubule disruption and mitotic catastrophe.
European journal of medicinal chemistry. 46(9):4595-607 [DOI] 10.1016/j.ejmech.2011.07.039. [PMID] 21840628.
2011
Synthesis, evaluation and structural studies of antiproliferative tubulin-targeting azetidin-2-ones.
Bioorganic & medicinal chemistry. 19(7):2306-25 [DOI] 10.1016/j.bmc.2011.02.022. [PMID] 21397510.
2010
Lead identification of conformationally restricted benzoxepin type combretastatin analogs: synthesis, antiproliferative activity, and tubulin effects.
Journal of enzyme inhibition and medicinal chemistry. 25(2):180-94 [DOI] 10.3109/14756360903169659. [PMID] 20222762.
2010
Lead identification of conformationally restricted β-lactam type combretastatin analogues: synthesis, antiproliferative activity and tubulin targeting effects.
European journal of medicinal chemistry. 45(12):5752-66 [DOI] 10.1016/j.ejmech.2010.09.033. [PMID] 20933304.
2010
Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agents.
Journal of medicinal chemistry. 53(24):8569-84 [DOI] 10.1021/jm101115u. [PMID] 21080725.
2010
The vascular targeting agent combretastatin-A4 and a novel cis-Restricted {beta}-Lactam Analogue, CA-432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance.
The Journal of pharmacology and experimental therapeutics. 335(2):302-13 [DOI] 10.1124/jpet.110.170415. [PMID] 20699436.
2009
The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
Biochemical pharmacology. 77(3):310-21 [DOI] 10.1016/j.bcp.2008.10.008. [PMID] 19014913.
2009
The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia.
Cancer research. 69(21):8366-75 [DOI] 10.1158/0008-5472.CAN-09-0131. [PMID] 19826055.
2008
BubR1 is required for a sustained mitotic spindle checkpoint arrest in human cancer cells treated with tubulin-targeting pyrrolo-1,5-benzoxazepines.
Molecular pharmacology. 73(2):419-30 [PMID] 17991869.
2007
STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.
The Journal of pharmacology and experimental therapeutics. 321(1):288-97 [PMID] 17202400.
2006
Identification of tubulin as the molecular target of proapoptotic pyrrolo-1,5-benzoxazepines.
Molecular pharmacology. 70(1):60-70 [PMID] 16571652.
2005
The pyrrolo-1,5-benzoxazepine, PBOX-6, inhibits the growth of breast cancer cells in vitro independent of estrogen receptor status and inhibits breast tumour growth in vivo.
Oncology reports. 14(5):1357-63 [PMID] 16211309.
2004
Selective induction of apoptosis by the pyrrolo-1,5-benzoxazepine 7-[[dimethylcarbamoyl]oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine (PBOX-6) in Leukemia cells occurs via the c-Jun NH2-terminal kinase-dependent phosphorylation and inactivation of Bcl-2 and Bcl-XL.
The Journal of pharmacology and experimental therapeutics. 310(3):1084-95 [PMID] 15143129.
2003
Elevated expression and altered processing of fibulin-1 protein in human breast cancer.
British journal of cancer. 88(6):871-8 [PMID] 12644824.
2003
Fibulins: physiological and disease perspectives.
EMBO reports. 4(12):1127-31 [PMID] 14647206.
2001
Human fibulin-4: analysis of its biosynthetic processing and mRNA expression in normal and tumour tissues.
FEBS letters. 489(1):59-66 [PMID] 11231014.

Contact Details

Phones:
Business:
(352) 294-8409
Emails:
Addresses:
Business Mailing:
PO Box 100245
GAINESVILLE FL 32610
Business Street:
1200 Newell Drive, ARB R3-234
Gainesville FL 32610